Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Mutations in the leucine‐rich repeat kinase 2 gene (LRRK2) are the most common genetic cause of Parkinson's disease (PD). Unexpectedly, tau pathology has been reported in a subset of LRRK2 mutation carriers. Methods: To estimate the frequency of pathogenic LRRK2 mutations and to evaluate the association of common LRRK2 variants with risk of primary tauopathies, we studied 1039 progressive supranuclear palsy (PSP) and 145 corticobasal degeneration patients from the Mayo Clinic Florida brain bank and 1790 controls ascertained at Mayo Clinic. Sanger sequencing of LRRK2 exons 30, 31, 35, and 41 was performed in all patients, and genotyping of all 17 known exonic variants with minor allele frequency >0.5% was performed in patients and controls. Results: LRRK2 mutational screening identified 2 known pathogenic mutations (p.G2019S and p.R1441C), each in 1 PSP patient, the novel p.A1413T mutation in a PSP patient and the rare p.R1707K mutation in a corticobasal degeneration patient. Both p.A1413T and p.R1707K mutations were predicted damaging by at least 2 of 3 prediction programs and affect evolutionary conserved sites of LRRK2. Association analysis using common LRRK2 variants only showed nominal association of the p.L153L variant with PSP. Conclusions: Our study confirms the presence of pathogenic and potentially pathogenic LRRK2 mutations in pathologically confirmed primary tauopathies, albeit with low frequency. In contrast to PD, common LRRK2 variants do not appear to play a major role in determining PSP and corticobasal degeneration risk. © 2016 International Parkinson and Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904 · cited 11×
“Although predominantly associated with Lewy body (LB) pathology and clinical typical parkinsonism, LRRK2 mutations can present with other non-PD manifestations including significant taupositive aggregates and NFT.4 The search for LRRK2 mutations in other non-PD populations has resulted in the identification of mutatio…”
BackgroundInfluentialSelf-citationInternational Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · cited 10×
“Although predominantly associated with Lewy body (LB) pathology and clinical typical parkinsonism, LRRK2 mutations can present with other non-PD manifestations including significant taupositive aggregates and NFT.4 The search for LRRK2 mutations in other non-PD populations has resulted in the identification of mutatio…”
MethodInfluentialSelf-citation(2007) · YUHSpace (Yonsei University Medical Library) · doi:10.1016/s1474 · Cited by 641
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324
Self-citation
Cited by
Challenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874
The genetic architecture of Parkinson's disease
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30287-x · Cited by 1,114
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“The latter appears highly sensitive to tau aggregation processes in patients with PSP.126 Postmortem studies suggest that the loss of cholinergic neurons from the nucleus basalis occurs early in PD. Cholinergic terminal function in PD has been assessed with 11C-NMP4A and 11C-PMP PET, markers of acetylcholine esterase…”
InfluentialLang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study
Jabbari, E., Koga, S., Valentino, R. R., Reynolds, R. H., Ferrari, R., Tan, M. M. X., Rowe, J. B., Dalgard, C. L., Scholz, S. W., Dickson, D. W., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30394-x · Cited by 111
Self-citation
Metadata
- Authors
- Sanchez‐Contreras, M., Heckman, M. G., Tacik, P., Diehl, N., Brown, P. H., Soto‐Ortolaza, A. I., Christopher, E. A., Walton, R. L., Ross, O. A., Golbe, L. I., Graff‐Radford, N., Wszolek, Z. K., Dickson, D. W., & Rademakers, R.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2016-10-06
- Volume
- 32
- Issue
- 1
- Pages
- 115-123
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2529124356
- Cited by
- 68
- References
- 5
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.